MetaCap

Polaryx Therapeutics (PLYX) vs Zhengye Biotechnology (ZYBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $66.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLYX-96.20%ZYBT+57.45%
+795%+328%-139%
Feb 2, 20261 yearNov 20, 2026
PLYX-85.07%ZYBT+76.19%
+154%+29%-96%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLYX versus ZYBT key metrics
MetricPLYXZYBT
Share price$1.33$1.48
Market cap$66.30M$70.14M
1-day change-11.92%-2.63%
YTD return—+28.70%
1-year return—-30.84%
EPS (TTM)$-0.18$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.64M
Revenue growth (YoY)—-34.83%
Net income (latest FY)$-8.98M$-9.98M
Gross margin—20.51%
Operating margin—-60.60%
Net margin—-59.99%
52-week high$48.91$8.01
52-week low$1.30$0.616
Distance from 52-week high-97.28%-81.52%
Analyst consensusnone—
Avg. price target upside+463.91%—
Average volume36.42K569.22K
Shares outstanding49.85M47.39M
Employees2269
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About Zhengye Biotechnology

ZYBT stock →

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees

PLYX vs ZYBT FAQ

Which is bigger, Polaryx Therapeutics or Zhengye Biotechnology?

Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $66.30M for Polaryx Therapeutics (PLYX).

Are Polaryx Therapeutics and Zhengye Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons